DK1171108T3 - Kombinationspræparat til behandling af malaria - Google Patents

Kombinationspræparat til behandling af malaria

Info

Publication number
DK1171108T3
DK1171108T3 DK00921746T DK00921746T DK1171108T3 DK 1171108 T3 DK1171108 T3 DK 1171108T3 DK 00921746 T DK00921746 T DK 00921746T DK 00921746 T DK00921746 T DK 00921746T DK 1171108 T3 DK1171108 T3 DK 1171108T3
Authority
DK
Denmark
Prior art keywords
treatment
malaria
combination preparation
proguanil
primaquine
Prior art date
Application number
DK00921746T
Other languages
Danish (da)
English (en)
Inventor
Jeffrey David Chulay
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DK1171108T3 publication Critical patent/DK1171108T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK00921746T 1999-04-09 2000-04-05 Kombinationspræparat til behandling af malaria DK1171108T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12867299P 1999-04-09 1999-04-09
PCT/US2000/009091 WO2000061133A1 (fr) 1999-04-09 2000-04-05 Preparation combinee a utiliser pour le traitement de la malaria

Publications (1)

Publication Number Publication Date
DK1171108T3 true DK1171108T3 (da) 2003-10-06

Family

ID=22436426

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00921746T DK1171108T3 (da) 1999-04-09 2000-04-05 Kombinationspræparat til behandling af malaria

Country Status (23)

Country Link
US (1) US6413993B1 (fr)
EP (1) EP1171108B1 (fr)
JP (1) JP2002541196A (fr)
KR (1) KR100613805B1 (fr)
CN (1) CN1152676C (fr)
AT (1) ATE241971T1 (fr)
AU (1) AU758167B2 (fr)
BR (1) BR0009676A (fr)
CA (1) CA2369089A1 (fr)
CZ (1) CZ294903B6 (fr)
DE (1) DE60003175T2 (fr)
DK (1) DK1171108T3 (fr)
ES (1) ES2199817T3 (fr)
HU (1) HUP0200842A3 (fr)
IL (2) IL145609A0 (fr)
MX (1) MXPA01010125A (fr)
NO (1) NO20014806L (fr)
NZ (1) NZ514353A (fr)
PL (1) PL350987A1 (fr)
PT (1) PT1171108E (fr)
TR (1) TR200102843T2 (fr)
WO (1) WO2000061133A1 (fr)
ZA (1) ZA200108254B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9224739D0 (en) * 1992-11-26 1993-01-13 Wellcome Found Medicaments
CN102088956A (zh) * 2008-05-09 2011-06-08 托马有限公司 氯胍用于治疗皮肤/粘膜疾病
AU2009273747A1 (en) * 2008-07-25 2010-01-28 Alphapharm Pty Ltd Atovaquone with a particle size diameter range (D90) of greater than 3 um to about 10 um
ES2517366T3 (es) * 2009-08-20 2014-11-03 Ipca Laboratories Limited Nuevo complejo para el tratamiento y/o profilaxis de infecciones parasitarias
EP3415147B1 (fr) * 2016-02-12 2025-04-02 Kao Corporation Inhibiteur de dégradation de mélanine
EP3522825B1 (fr) * 2016-10-05 2023-06-07 Titan Pharmaceuticals, Inc. Dispositifs implantables pour l'administration de médicaments caractérisés par une moindre libération massive et soudaine
WO2018204563A1 (fr) * 2017-05-03 2018-11-08 The Johns Hopkins University Atovaquone intramusculaire pour la prophylaxie du paludisme
CN107737108B (zh) * 2017-12-17 2018-06-26 姚蕾 一种治疗心肌梗死后心室重塑的口服药物组合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9224739D0 (en) 1992-11-26 1993-01-13 Wellcome Found Medicaments
JPH0873355A (ja) * 1994-09-02 1996-03-19 Mitsui Toatsu Chem Inc 抗マラリア薬耐性克服剤

Also Published As

Publication number Publication date
DE60003175T2 (de) 2004-04-01
NZ514353A (en) 2003-10-31
MXPA01010125A (es) 2002-06-04
CA2369089A1 (fr) 2000-10-19
JP2002541196A (ja) 2002-12-03
TR200102843T2 (tr) 2002-01-21
KR20010108468A (ko) 2001-12-07
IL145609A (en) 2006-04-10
KR100613805B1 (ko) 2006-08-18
HK1041638A1 (en) 2002-07-19
NO20014806L (no) 2001-12-05
CN1346267A (zh) 2002-04-24
NO20014806D0 (no) 2001-10-03
PT1171108E (pt) 2003-10-31
ZA200108254B (en) 2003-03-26
ES2199817T3 (es) 2004-03-01
HUP0200842A3 (en) 2006-07-28
AU758167B2 (en) 2003-03-20
CZ20013646A3 (cs) 2002-06-12
CZ294903B6 (cs) 2005-04-13
US6413993B1 (en) 2002-07-02
AU4202200A (en) 2000-11-14
IL145609A0 (en) 2002-06-30
EP1171108A1 (fr) 2002-01-16
CN1152676C (zh) 2004-06-09
ATE241971T1 (de) 2003-06-15
BR0009676A (pt) 2002-09-03
EP1171108B1 (fr) 2003-06-04
DE60003175D1 (de) 2003-07-10
WO2000061133A1 (fr) 2000-10-19
HUP0200842A2 (hu) 2002-07-29
PL350987A1 (en) 2003-02-24

Similar Documents

Publication Publication Date Title
BR9809425A (pt) Conjugados alfa interferon-polietilenoglicol para terapia de infecção
GEP20053602B (en) Aripiprazole for Oral Administration
DK0998287T3 (da) Anvendelse af levobupivacain
WO2004096818A3 (fr) Procede et compositions pour l'identification de composes therapeutiques anti-vih
LU91327I2 (fr) Vaccin papillomavirus humain Ätypes 56,11,16,18Ü(recombinant, adsorbé)
BR0108210A (pt) Vacina contra o vìrus da imunodeficiência humana
DK1171108T3 (da) Kombinationspræparat til behandling af malaria
AU2002343321A8 (en) Isolation and purification of p. falciparum merozoite protein-142 vaccine
PT966285E (pt) Utilizacao de (+)mefloquina para o tratamento da malaria
EE05241B1 (et) Distamtsiini a-halogenoakrlolderivaadi kasutamine
NO20024255D0 (no) HIV-immun adjuvansterapi
EA200200853A1 (ru) Применение 2-метилтиазолидин-3,3-дикарбоновой кислоты (2-мтдк) и/или ее физиологически совместимых солей для лечения и/или предупреждения рака
AU2003223686A1 (en) Immunogenic agent therapy using plasmapheresis or exchange transfusion
DE60017183D1 (de) Implantierbarer zweikammerherzstimmulator
DK1399143T3 (da) Anvendelsen af Acetyl L-carnitin til fremstilling af et lægemiddel til behandling af anhedoni
BRPI0414853A (pt) copolìmeros de 1-vinilpirrolidin-2-ona/ésteres
DK1150981T3 (da) Terapeutisk necleosidforbindelse
NO20050445L (no) Synergistisk interaksjon mellom abacavir og alovudin
AU2002328253A1 (en) Pna conjugate for the treatment of diseases associated with hiv
UA38042A (uk) Протифібриляторний препарат трамадол
EP1383563A4 (fr) Methodes de traitement du vih et d'autres virus
ITMI992410A0 (it) Vaccino per hiv
ZA200301175B (en) Malaria immunogen and vaccine.
AU2002308925A1 (en) Blood group-free human blood plasma and the preparation method thereof
UA38006A (uk) Хондропротективний препарат